South Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July.
SEOUL - South Korea’s Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July.
FILE PHOTO: The logo of Celltrion is seen at the company's headquarters in Incheon, South Korea, Oct, 28, 2016. REUTERS/Kim Hong-Ji Drugmakers worldwide are rushing to develop treatments for the flu-like illness that has caused more than 371,000 deaths globally. Celltrion said its pre-clinical study showed improved recovery in runny nose, cough and body aches after the first day of treatment, and clearing of lung inflammation within six days. The study was conducted with ferrets and will be expanded to hamsters, mice and monkeys before clinical trials, Celltrion and study collaborator Chungbuk National University College of Medicine said in a statement. Celltrion is considering running clinical trials in South Korea or abroad, Kwon Ki-sung, head of Celltrion’s R&D unit, told Reuters. “ has the capability to roll out mass production of the therapeutic antibody treatment once it is ready,” he said in the statement.President Moon Jae-in in April pledged 210 billion won in funding to develop COVID-19 drugs, hoping to replicate the country’s success in COVID-19 test kits. Rigorous testing and tracking was instrumental in bringing the novel coronavirus virus under control in South Korea, which at one point experienced the biggest outbreak outside China, where the virus was first reported.U.S drugmaker Gilead Science Inc has reported promising early trial results for its treatment remdesivir, prompting emergency approval in the United States and Japan. South Korea also said last week it would request imports of remdesivir. Other South Korean pharmaceutical firms such as SK Bioscience and Green Cross Corp are at the beginning stage of coronavirus vaccine development. SK Bioscience last month received $3.6 million in research funding from the Bill & Melinda Gates Foundation to develop a COVID-19 vaccine. Reporting by Joyce Lee and Heekyong Yang; Additional reporting by Hyunjoo in; Editing by Himani Sarkar and Christopher Cushing
Please follow us on Google to support us United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Hundreds of South Korean schools closed amid spike in COVID-19 cases - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Read more »
Asia Today: 27 new cases in South Korea, 2 in ChinaSouth Korea reports 27 new cases of the coronavirus, including 21 from the densely populated Seoul metropolitan area, where officials are scrambling to stem transmissions linked to clubgoers and warehouse workers.
Read more »
Bars, gyms and restaurants in South Korea to keep a QR-code log of customersRecreational venues in South Korea, including bars, nightclubs and indoor gyms, will be required to keep a QR code-based customer log, health officials said. This data will be automatically erased after four weeks to safeguard customer information.
Read more »
South Korea's Celltrion says COVID-19 drug shows drop in viral load in animal testingSouth Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.
Read more »
Samsung to add new memory chip line in South Korea as COVID-19 boosts demandSamsung Electronics Co Ltd said on Monday it has begun construction of a new domestic production line for NAND flash memory chips, betting on demand for personal computers and servers as the coronavirus prompts more people to work from home.
Read more »